Immunotherapy has also been carried out in a series of studies in BRCA, although its effect is not as significant as in lung cancer, melanoma, and other tumors, it has achieved a certain effect in triple-negative BRCA (23, 24), while the results in HR-positive/HER2-negative and HER2-positive BRCA are still immature or the efficacy needs further exploration (25). This evidence concerns the gene ERBB2 and lung carcinoma.